Plain-English translation of NCT05880537 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing a new type of blood vessel graft called Nexeon AVX Decellularized Femoral Artery—made from human tissue that has been specially processed in a lab. The graft is used to create access for hemodialysis (a treatment that filters waste from your blood when your kidneys no longer work). Researchers want to learn whether this treatment is safe and works well for patients who need dialysis.
People with end-stage kidney disease need reliable access to their bloodstream for dialysis treatments, but creating this access can be challenging. This study exists to see whether this new type of processed human tissue graft is a better option than current choices.
You likely qualify if…
You likely don't qualify if…
You would receive the new blood vessel graft during a surgical procedure to create dialysis access. After the procedure, you would return to the clinic for scheduled follow-up visits so the research team can monitor how well the graft is working and check for any safety concerns. The study is observational, meaning researchers will track your progress and collect data about how the graft performs over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Sponsor
LifeNet Health
Enrollment target
~100 participants
Started
June 2023
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kimberly Dorsch
LifeNet Health
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.